白细胞亚群早期恢复与不可手术II/III期NSCLC多模式治疗后有利无进展生存相关:一项前瞻性探索性研究
该前瞻性探索性研究分析了20例不可手术II/III期非小细胞肺癌(NSCLC)患者在多模式治疗前、中及治疗后1年内9个时间点的外周血白细胞亚群动态变化,并分析其与无进展生存(PFS)和总生存(OS)的相关性。结果显示放疗结束后至6个月内绝对淋巴细胞计数(ALC)升高是PFS的预测因素,放疗后3周CD3+总T细胞和CD8+细胞毒性T细胞绝对计数早期恢复可区分PFS有利(≥12个月)的患者。结论提示CD8+T细胞计数早期升高和IL-6血浆浓度变异性这两个临床常规可评估的参数可用于预测患者结局。
要点
- 放疗结束后至6个月内ALC升高是PFS的预测因素。
- 放疗后3周CD3+总T细胞和CD8+细胞毒性T细胞绝对计数早期恢复区分PFS有利(≥12个月)患者。
- CD8+T细胞计数早期升高和IL-6浓度变异性与有利或不良结局相关。
核心结论
- 结果提示两个临床常规评估的参数可用于预测患者结局:CD8+T细胞淋巴细胞计数早期升高和IL-6血浆浓度变异性,分别与根治性治疗后有利和不良结局相关,且独立于治疗方案。
研究设计与样本
- 前瞻性探索性研究,分析20例不可手术II/III期NSCLC患者的外周血,患者接受胸部放疗(RT)、同步放化疗(cCRT)或cCRT联合免疫检查点抑制治疗。
- 外周血在治疗前、治疗中及治疗后长达1年共9个时间点采集,采用多色流式细胞术分析。
- 统计分析白细胞亚群、IL-6、无进展生存(PFS)和总生存(OS)。
主要发现
- 放疗结束后至6个月内绝对淋巴细胞计数(ALC)升高是PFS的预测因素。
- 基线淋巴细胞计数与PFS或OS无显著相关性。
- 放疗后3周CD3+总T细胞和CD8+细胞毒性T细胞绝对计数早期恢复可区分PFS有利(≥12个月)的患者与所有其他患者。
- 判别分析识别B细胞、中性粒细胞-淋巴细胞比值(NLR)、CD4+T辅助细胞和NK细胞为有利PFS的预测因素。
- 放疗结束后6个月内连续测量的IL-6血浆浓度高变异性与PFS负相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We explored the dynamic changes of major leukocyte subsets during definitive treatment of patients with inoperable stage II/III NSCLC lung cancer and correlated it to survival to identify subpopulations associated with maximal patient benefit. METHODS: We analyzed peripheral blood of 20 patients, either treated with thoracic radiotherapy (RT), concurrent chemo-radiotherapy (cCRT), or cCRT with additional immune-checkpoint inhibition therapy. Peripheral blood of 20 patients was collected at 9 timepoints before, during, and up to 1 year post treatment and analyzed by multi-color flow cytometry. Statistical analysis was conducted for leukocyte subpopulations, IL-6, progression-free survival (PFS) and overall survival (OS). RESULTS: Increase of absolute lymphocyte counts (ALC) after the end of RT until 6 months thereafter was a predictor of PFS. Baseline lymphocyte counts showed no significant correlation to PFS or OS. Early recovery of absolute counts (AC) at 3 weeks after RT, total CD3 + T-cells, and CD8 + cytotoxic T-cells distinguished those patients with favorable PFS (≥ 12 months) from all other patients. Discriminant analysis identified B-cells, neutrophil-lymphocyte-ratio (NLR), CD4 + T-helper-cells, and NK-cells as predictors of favorable PFS. High variability in IL-6 plasma concentration of consecutive measurements within 6 months after the end of RT correlated negatively with PFS. CONCLUSION: Our results suggest that two parameters commonly assessed in clinical routine can be used to predict patient outcome. These are: early increase in CD8 + T-cell lymphocyte count and variability in IL-6 plasma concentration, that are correlated to patients with favorable, respectively, poor outcome after definitive therapy independent of treatment regimen.
引用
- Hofer TP, Nieto AE, Käsmann L, et al. Early recovery of leukocyte subsets is associated with favorable progression-free survival in patients with inoperable stage II/III NSCLC after multimodal treatment: a prospective explorative study. Radiat Oncol. 2025. PMID: 40114261. doi:10.1186/s13014-025-02620-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。